Search

Codexis Inc

Slēgts

SektorsVeselības aprūpe

1.66 6.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.6600000000000001

Max

1.69

Galvenie mērījumi

By Trading Economics

Ienākumi

-3.3M

-12M

Pārdošana

-333K

15M

EPS

-0.13

Peļņas marža

-80.489

Darbinieki

146

EBITDA

-4.3M

-11M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+319.16% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

13M

174M

Iepriekšējā atvēršanas cena

-4.75

Iepriekšējā slēgšanas cena

1.66

Ziņu noskaņojums

By Acuity

31%

69%

113 / 340 Rangs Healthcare

Codexis Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 19:46 UTC

Correlated Moves

Codexis Inc shares are higher today, reflecting strong momentum. This aligns with a broader biotechnology trend, supported by gains in the ARK Genomic Revolution ETF.

2026. g. 20. aug. 19:16 UTC

Codexis Inc. shares are roughly flat as no specific news emerged. Intraday fluctuations ranged from a high of 8.23% to a low of -1.27%.

2026. g. 19. aug. 20:02 UTC

Correlated Moves
News

Codexis Inc shares are higher today, supported by positive momentum in the genomics sector and the performance of the ARK Genomic Revolution ETF.

2026. g. 18. aug. 19:41 UTC

Codexis Inc shares are trading lower during Tuesday's session, continuing a decline since Monday's close amid broader market concerns over rising treasury yields and inflation.

2026. g. 17. aug. 19:56 UTC

News

Codexis shares are higher as Piper Sandler maintains Overweight rating and lowers price target to $8.00 from $9.00. Positive investor sentiment persists.

2026. g. 14. aug. 19:46 UTC

Codexis Inc shares are lower, reflecting broader market weakness amid an unexpected decline in U.S. retail sales for July.

2026. g. 13. aug. 19:51 UTC

News

Codexis reported Q2 2026 revenue of $14.9 million and a net loss of $12.0 million. Shares are trading roughly flat during Thursday's session.

2026. g. 12. aug. 20:01 UTC

News

Codexis reported a narrower net loss of $12 million and reaffirmed revenue guidance of $72 million to $76 million, contributing to gains during Wednesday's session.

2026. g. 11. aug. 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

2026. g. 10. aug. 19:21 UTC

News

Codexis Inc shares are higher following a positive earnings report, with a loss per share of -$0.10, better than analysts' expectations of -$0.11.

2026. g. 7. aug. 19:36 UTC

Codexis Inc shares are lower, reflecting broader market trends amid uncertainty over monetary policy and a weaker-than-expected jobs report.

2026. g. 6. aug. 19:56 UTC

Codexis Inc shares are higher during Thursday's session, continuing an upward trend. The stock remains below its 20-day moving average.

2026. g. 5. aug. 20:06 UTC

Codexis Inc shares are higher today, reflecting positive market sentiment amid a broader uptick in equities. No specific news was identified for the movement.

2026. g. 4. aug. 19:56 UTC

Codexis Inc. shares are trading roughly flat, with no specific news identified. The stock remains below its 20-day moving average and near its one-month range low.

2026. g. 3. aug. 19:44 UTC

News

Codexis Inc has appointed David Butler, PhD, to its Strategic Advisory Board. Shares are advancing, though still below the 20-day moving average.

2026. g. 31. jūl. 20:02 UTC

Codexis Inc shares are trading lower today, continuing a broader decline. The stock is near the lower end of its one-month range.

2026. g. 30. jūl. 20:09 UTC

Codexis Inc shares are higher today, continuing their rise since Wednesday's close. Broader market volatility is influenced by mixed economic signals.

2026. g. 29. jūl. 19:47 UTC

Macro Event

Codexis Inc shares are lower amid broader market declines and heightened volatility following the Federal Reserve's decision to keep interest rates steady.

2026. g. 28. jūl. 19:51 UTC

Codexis Inc. shares are trading lower today, reflecting a downward trend since Monday, with a notable decline from an earlier session high.

2026. g. 27. jūl. 19:21 UTC

News

Codexis Inc shares are higher today, supported by early customer orders and interest from CDMOs. The stock remains up since Friday's close.

2026. g. 24. jūl. 19:01 UTC

News

Codexis Inc shares are lower following a public offering of 16.67 million shares at $1.50 each, below Thursday's close of $1.99.

2026. g. 23. jūl. 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

2026. g. 22. jūl. 20:01 UTC

Codexis Inc shares are lower during Wednesday's session, continuing a trend of declines since Tuesday's close. The stock remains below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Codexis Inc Prognoze

Cenas mērķis

By TipRanks

319.16% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD  319.16%

Augstākais 11 USD

Zemākais 2 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Codexis Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

113 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat